A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

NCT07556549 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer ALK-positive

Interventions

DRUG: Lorlatinib

Sponsor

Pfizer